A small Seattle biotech wants to take on GlaxoSmithKline's emerging Shingrix blockbuster. RA Capital is on board

GlaxoSmithKline’s Shingrix has quickly become one of the company’s best-selling products since first winning FDA approval in 2017. But a new biotech believes it can do better — and RA Capital is listening.